Kevin J Gilbert

US Patent:

6387893, May 14, 2002

Filed:

Sep 27, 2000

Appl. No.:

09/671520

Inventors:

Ben E. Evans - Lansdale PA
Jacob M. Hoffman - Lansdale PA
Kevin F. Gilbert - Barto PA
Kenneth E. Rittle - Green Lane PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 3155

US Classification:

51421202, 51421103, 51421104, 51421204, 5142245, 514267, 514278, 540485, 540495, 540543, 540547, 544249, 544315, 544318

Abstract:

Spirotricyclic azacycloalkyl compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds is also described. One application of these compounds, which are alpha 1a adrenergic receptor antagonists, is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

US Patent:

8461107, Jun 11, 2013

Filed:

Apr 16, 2009

Appl. No.:

12/989672

Inventors:

Nigel J. Liverton - Harleysville PA, US
John A. McCauley - Maple Glen PA, US
John W. Butcher - Telford PA, US
Kevin F. Gilbert - Barto PA, US
Charles J. McIntyre - Lansdale PA, US
Michael T. Rudd - Collegeville PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 38/00

US Classification:

514 37

Abstract:

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

US Patent:

20100099695, Apr 22, 2010

Filed:

Oct 23, 2007

Appl. No.:

12/447342

Inventors:

Nigel J. Liverton - Harleysville PA, US
Vincenzo Summa - Rome, IT
Maria Emilia Di Francesco - Rome, IT
Marco Ferrara - Rome, IT
Kevin F. Gilbert - Barto PA, US
Steven Harper - Rome, IT
John A. McCauley - Maple Glen PA, US
Charles A. McIntyre - Lansdale PA, US
Alessia Petrocchi - Rome, IT
Marco Pompei - Rome, IT
Joseph J. Romano - Rome, IT
Michael T. Rudd - Collegeville PA, US
John W. Butcher - Telford PA, US
M. Katharine Holloway - Lansdale PA, US

International Classification:

A61K 31/439
C07D 513/18
C07D 513/08
A61K 31/407
A61K 31/4748
A61P 31/12

US Classification:

514281, 540456, 514293, 514411, 514286

Abstract:

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

US Patent:

20130090352, Apr 11, 2013

Filed:

Jun 10, 2011

Appl. No.:

13/704259

Inventors:

Kevin F. Gilbert - Barto PA, US
Scott D. Kuduk - Harleysville PA, US

International Classification:

C07D 405/14
C07D 401/14
C07D 471/04
C07D 401/06

US Classification:

514300, 546169, 514314, 546121

Abstract:

The present invention is directed to tetrahydroquinoline amide compounds of formula (I) (Formula should be inserted here) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

US Patent:

20130178413, Jul 11, 2013

Filed:

Sep 16, 2011

Appl. No.:

13/825245

Inventors:

John A. McCauley - Maple Glen PA, US
Nigel J. Liverton - Harleysville PA, US
Michael T. Rudd - Collegeville PA, US
Kevin F. Gilbert - Barto PA, US
Marco Ferrara - Milanese, IT
Vincenzo Summa - Roma, IT
Benedetta Crescenzi - Paris, FR

International Classification:

A61K 38/07
C07K 5/103
A61K 45/06
C07K 5/107

US Classification:

514 43, 530330

Abstract:

The present invention relates to macrocyclic compounds of formula I that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.

US Patent:

54647886, Nov 7, 1995

Filed:

Mar 24, 1994

Appl. No.:

8/217270

Inventors:

Mark G. Bock - Hatfield PA
Ben E. Evans - Lansdale PA
J. Christopher Culberson - Hatfield PA
Kevin F. Gilbert - Bechtelsville PA
Kenneth E. Rittle - Green Lane PA
Peter D. Williams - Harleysville PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D27300
C07D41300
C07D45100

US Classification:

514252

Abstract:

Compounds of the formula X--Y--R, or the pharmaceutically acceptable salts and esters thereof, wherein X is ##STR1## Y is --SO. sub. 2 --, --(CH. sub. 2). sub. p -- or --CO--(CH. sub. 2). sub. p --; R is unsubstituted or substituted phenyl where said substitutents are one or more of R. sup. 5, R. sup. 6 or R. sup. 7 ; R. sup. 1 is hydrogen, cyano, phenyl,--CONHR. sup. 2, --CONR. sup. 2 R. sup. 2, --(CH. sub. 2). sub. m --OR. sup. 2, --(CH. sub. 2). sub. p --S(O). sub. r --R. sup. 2, --(CH. sub. 2). sub. m --CO. sub. 2 R. sup. 2, --(CH. sub. 2). sub. m --N. sub. 3, --(CH. sub. 2). sub. m --NH. sub. 2 or --(CH. sub. 2). sub. m --NR. sup. 2 R. sup. 2 ; R. sup. 2 is hydrogen, C. sub. 3-8 cycloalkyl or C. sub. 1-5 alkyl; R. sup. 5 and R. sup. 6 are each independently selected from hydrogen, C. sub.

US Patent:

57565040, May 26, 1998

Filed:

Sep 23, 1996

Appl. No.:

8/718415

Inventors:

Mark G. Bock - Hatfield PA
Ben E. Evans - Lansdale PA
J. Christopher Culberson - Hatfield PA
Kevin F. Gilbert - Bechtelsville PA
Kenneth E. Rittle - Green Lane PA
Peter D. Williams - Harleysville PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31495
C07D24104
C07D40112
C07D40312

US Classification:

514252

Abstract:

Compounds of the formula X--Y--R, or the pharmaceutically acceptable salts and esters thereof, wherein X is ##STR1## Y is --SO. sub. 2 --, --(CH. sub. 2). sub. p -- or --CO--(CH. sub. 2). sub. p --; R is unsubstituted or substituted phenyl where said substitutents are one or more of R. sup. 5, R. sup. 6 or R. sup. 7 ; R. sup. 1 is hydrogen, cyano, phenyl, --CONHR. sup. 2, --CONR. sup. 2 R. sup. 2, --(CH. sub. 2). sub. m --OR. sup. 2, --(CH. sub. 2). sub. p --S(O). sub. r --R. sup. 2, --(CH. sub. 2). sub. m --CO. sub. 2 R. sup. 2, --(CH. sub. 2). sub. m --N. sub. 3, --(CH. sub. 2). sub. m --NH. sub. 2 or --(CH. sub. 2). sub. m --NR. sup. 2 R. sup. 2 ; R. sup. 2 is hydrogen, C. sub. 3-8 cycloalkyl or C. sub. 1-5 alkyl; R. sup. 5 and R. sup. 6 are each independently selected from hydrogen, C. sub.

US Patent:

56807708, Oct 28, 1997

Filed:

Nov 4, 1996

Appl. No.:

8/743560

Inventors:

Richard M. Hall - Hockessin DE
Kevin C. Gilbert - Newark DE

Assignee:

Freeze Service, Inc. - Wilmington DE

International Classification:

F25C 100

US Classification:

62293

Abstract:

Apparatus for freezing liquid in a fluid conducting pipe comprises a freeze jacket having two halves for releasably surrounding a section of pipe. Each jacket half includes outwardly extending flanges in abutting relationship when the jacket halves surround the section of pipe, and structure is provided on the flanges for releasably securing the two jacket halves together around the pipe. The jacket has an internal cylindrical freeze cavity adjacent the pipe and this cavity receives and retains a supply of liquid nitrogen. The cylindrical freeze cavity is defined in part by an inner two-part fixedly secured cylindrical sleeve, one half of the sleeve being associated with each half of the jacket. Insulation is positioned on the outside of each fixed sleeve half between that sleeve and an outer removable cover. Removal of the cover enables internal structural repairs and exposes the insulation for removal and replacement with new insulation.